Mihael Polymeropoulos, Vanda Pharmaceuticals CEO
April 11, 2022 11:17 AM EDTUpdated April 12, 08:19 AM
FDA+

Van­da takes FDA to court again, this time seek­ing more in­fo on a re­jec­tion let­ter

Zachary Brennan

Senior Editor

Af­ter a pre­vi­ous court loss to FDA in ear­ly 2020 over a clin­i­cal hold, Van­da Phar­ma­ceu­ti­cals re­turned to sue the agency …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times